Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Frontiers in Oncology|November 29, 2023
Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinomaElena Mairinger, Michael Wessolly, Paul Buderath, et al.
Cancers|January 11, 2022
Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian CancerVictoria Tserpeli, Dimitra Stergiopoulou, Dora Londra, et al.
Molecular Oncology|February 11, 2020
Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cellsMargarita Melnikova, Ulrike Sophie Wauer, Diana Mendus, et al.
Gynecologic Oncology|December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancerIgnace Vergote, Florian Heitz, Paul Buderath, et al.
Journal of Surgical Oncology|March 28, 2023
Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT databaseMaximilian Klar, Helmut Plett, Philipp Harter, et al.
Archives of Gynecology and Obstetrics|July 21, 2021
The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study groupAnnette Hasenburg, Hellmut Plett, Bernhard Krämer, et al.
Journal of Surgical Oncology|March 9, 2026
Fertility-Sparing Surgery, Treatment Strategies and Survival of Women With Malignant Ovarian Germ Cell Tumours-A Descriptive Analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie CORSETT DatabaseMaximilian Klar, Malak Moubarak, Philipp Harter, et al.
JCO Precision Oncology|June 12, 2026
Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 StudyMohamad Kayali, Eric Hahnen, Alexander Burges, et al.
The New England Journal of Medicine|December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerIsabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.
Journal of the National Cancer Institute|April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
Pageof 7